ABSTRACT
Objective:To evaluate the effect of Bushen-Tiaojing Decoction combined with estrogen and progesterone replacement therapy in the treatment of premature ovarian failure (POF). Methods:A total of 102 patients who met the inclusion criteria in our hospital from June 2017 to June 2018 were divided into two groups according to the random number table method, 51 cases in each group. The control group was treated with estrogen and progesterone replacement therapy. The study group was treated with Bushen-Tiaojing Decoction on the basis of the control group. Both groups were treated for 3 cycles. Before and after treatment, the TCM symptom scores were evaluated. The ovarian volume and the follicles number were monitored by ultrasound. The resistance index (RI), pulse index (PI) and end diastolic blood flow velocity (EDV) and peak systolic blood flow velocity (PSV) were measured and calculated by color Doppler ultrasound. The adverse reactions during treatment were observed and recorded, and the clinical efficacy was evaluated. Results:The total effective rate of the study group was 90.2% (46/51) and that of the control group was 70.6% (36/51), and the difference between the two groups was statistically significant ( χ2=6.220, P=0.013). The TCM symptoms scores in the study group after treatment were significantly lower than that of the control group ( t=9.216, P<0.01). After treatment, the ovarian volume (6.10 ± 1.53 cm 3vs. 5.19 ± 1.31 cm 3, t=3.226) of the study group was significantly larger than that of the control group, and the follicles number (5.72 ± 1.66 vs. 4.11 ± 0.98, t=5.964) was significantly more than that of the control group ( P<0.01). The RI (0.61 ± 0.04 vs. 0.69 ± 0.05, t=8.922), PI (1.30 ± 0.07 vs. 1.75 ± 0.09, t=28.186) of the study group were significantly lower than those in the control group ( P<0.01), EDV (7.53 ± 1.12 cm/s vs. 5.28 ± 1.02 cm/s, t=10.607), PSV (22.74 ± 3.19 cm/s vs. 19.33 ± 2.70 cm/s, t=5.827) were significantly higher than those in the control group ( P<0.01). The incidence of adverse reactions was 13.7% (7/51) in the study group and 9.8% (5/51) in the control group, and there was no significant difference between the two group ( χ2=0.378, P=0.539). Conclusions:Bushen-Tiaojing Decoction combined with estrogen and progesterone replacement can reduce the clinical symptoms of patients with POF, improve the blood flow of ovary and its interstitial artery, and has shown safety.
ABSTRACT
Objective To detect the polymorphism of CYP1A1-MspI gene in patients with ovarian cancer.and discuss the relationship between the polymorphism ofCYP1A1-MspI gene and correspond cases' general materials and clinical materials.Methods The free peripheral blood samples of 81 cases confirmed to be ovarian cancer by postoperative pathology were collected preoperatively and the polymorphism of CYP1A1-MspI gene was detected.The clinical materials of the 81 cases with different genotypes were compared.The relationship between the polymorphism and clinical materials was analyzed.Results Among the 81 cases of ovarian cancer,there were 47 cases of wild type-genotype A(T/T)(58%),25 cases of mutation heterozygosis-genotype B(T/C)(31%),and 9 cases of mutation homozygosis-genotype C(C/C)(11%).The genotypic frequency distribution in patients aged from 12 to 29 was one case of genotype A(2.1%),5 cases of genotype B(20.0%),and no case of genotype C.The genotypic frequency distribution in patients aged from 30 to 49 was 12 case of genotype A(25.5%),8 cases of genotype B(32.0%),and 3 cases of genotype C(33.3%).The genotypic frequency distribution in patients aged from 50 to 69 was 31 case of genotype A(66.0%),8 cases of genotype B(32.0%) and 4 cases of genotype C(44.4%).The genotypic frequency distribution in patients aged more than 70 years was 3 case were of genotype A(6.4%),4 cases of genotype B(16.0%),2 case of genotype C(22.2%).There were significant differences of the ages of onset between patients with different CYP1A1-MspI genotypes (P